NCT06219031Completed
A Study of the Tumor Microenvironment Affecting the Efficacy of Immunotherapy for Esophageal Cancer
Source: ClinicalTrials.gov · Last updated 26 Jan 2024
Brief summary (registry, in English)
This study is a retrospective study of clinical specimens. The study subjects were patients with esophageal cancer who received immunotherapy. Tumor tissue specimens surgically removed from patients before treatment will be collected primarily. In situ immunohistochemistry and multicolor immunofluorescence will be performed. We hypothesize that there are differences in lipid metabolism-related proteins in tumor tissues and immune cells in the preexisting tumor microenvironment in patients with esophageal cancer prior to immunotherapy, and that there is a link between such differences and the efficacy of immunotherapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 22 (actual)
- First submitted
- 12 Jan 2024
- Start date
- 1 Dec 2023
- Primary completion date
- 1 Dec 2023
- Lead sponsor
- Renmin Hospital of Wuhan University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06219031
What you commit to
- Study type: Observational
- Participants enrolled: 22
- From 1 Dec 2023 to the primary completion date, 1 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Preoperative neoadjuvant therapy
- Radical esophagectomy for esophageal cancer not performed prior to immunotherapy
Other illness
- Combined history of other malignant tumors
Other
- Clinical and pathologic information not available
- Unavailability of surgically resected tissue
Who the study is looking for
- Esophageal cancer patients receiving immunotherapy
- Radical esophagectomy for esophageal cancer at our institution prior to receiving immunotherapy
- Age greater than or equal to 18 years and less than or equal to 75 years old Imaging to assess patient efficacy after cycle 2 immunotherapy (CR/PR, SD/PD according to recist 1.1)
- Pathology Tumor tissue available
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renmin hosptial of Wuhan University Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.